<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03693885</url>
  </required_header>
  <id_info>
    <org_study_id>Lacarus</org_study_id>
    <nct_id>NCT03693885</nct_id>
  </id_info>
  <brief_title>Oxytocin Administration Prior Planned Caesarean Section</brief_title>
  <official_title>Mild Induced Labour Prior to Planned Caesarean Delivery to Improve Neonatal and Maternal Outcome - a Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Basel</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Zurich</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Spontaneous vaginal delivery of a healthy infant provokes a unique surge in stress hormone
      concentrations (e.g. AVP (arginine vasopressin) /copeptin) incommensurable with child or
      adult levels measured in any other situation. In contrast, infants delivered by primary
      caesarean section without preceding labour have low stress hormone concentrations at birth
      unless other stressors are present, including chorioamnionitis or intrauterine growth
      restriction. Infants delivered by caesarean section after a trial of labour show copeptin
      concentrations between these two extremes.

      Objectives:1) To reduce neonatal respiratory morbidity and admission to the Neonatal
      Intensive Care Unit and increase bonding and breastfeeding by triggering uterine contractions
      prior to planned caesarean delivery.

      2) To collect prospectively weight data of infants in the first 6 months of life to validate
      and expand our online neonatal weight calculator.

      Study design: Open label; randomised, placebo controlled trail Intervention: Oxytocin
      challenge test (OCT): Infusion of oxytocin 5 IU/500 ml Ringer® lactate at a rate of 12 ml/h
      and doubled every 10 min until three uterine contractions per 10-min interval are induced, at
      which point it will be stopped.

      Primary endpoint:

      - Incidence of neonatal respiratory morbidity

      Secondary endpoints:

        -  Umbilical cord blood copeptin levels

        -  Postnatal neonatal weight change

        -  Breastfeeding status
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of neonatal respiratory morbidity</measure>
    <time_frame>in the first 4 hours of life</time_frame>
    <description>Percentage of infants to be monitored or admitted to neonatology for respiratory distress syndrome</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Umbilical cord blood copeptin levels</measure>
    <time_frame>blood sample within 30 minutes after birth</time_frame>
    <description>copeptin levels in pmol/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Postnatal neonatal weight change</measure>
    <time_frame>postnatal day 1-4</time_frame>
    <description>Maximum neonatal weight change in percent of birth weight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Breastfeeding status</measure>
    <time_frame>1 year</time_frame>
    <description>Percentage of children who are not, partially or full breastfed</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1450</enrollment>
  <condition>Respiratory Insufficiency Syndrome of Newborn</condition>
  <condition>Breastfeeding Status</condition>
  <arm_group>
    <arm_group_label>OCT-group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oxytocin challenge test: Oxytocin 5 IU/500 ml Ringer® lactate will be infused at a rate of 12 ml/h and doubled every 10 min until it induced three uterine contractions per 10-min interval at which point it will stopped.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>standard procedure before planned caesarean section</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Oxytocin challenge test (OCT)</intervention_name>
    <description>Infusion of oxytocin 5 IU/500 ml Ringer® lactate at a rate of 12 ml/h and doubled every 10 min until three uterine contractions per 10-min interval are induced, at which point it will be stopped.</description>
    <arm_group_label>OCT-group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Singleton pregnancy &gt;34 weeks

          -  primary caesarean section, that is without preceding contractions or rupture of the
             membranes,

          -  absence of a contraindication to oxytocin

        Exclusion Criteria:

          -  Chromosomal aberration

          -  malformation,

          -  IUGR,

          -  Nonreassuring fetal heart rate pattern,

          -  Placenta praevia,

          -  maternal substance abuse,

          -  infections,

          -  hypertension,

          -  preeclampsia,

          -  diabetes type I or II,

          -  autoimmune disease (antiphospholipid syndrome, lupus erythematosus, etc.),

          -  renal disease,

          -  history of more than one previous caesarean section.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tilo Burkhardt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. of Obstetrics, University Hospital Zurich</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tilo Burkhardt, MD</last_name>
    <phone>+41 44 255 5192</phone>
    <email>tilo.burkhardt@usz.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sven Wellmann, Prof</last_name>
    <phone>+41 61 704 29 24</phone>
    <email>sven.wellmann@ukbb.ch</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Zurich, Department of Obstetrics</name>
      <address>
        <city>Zurich</city>
        <state>ZH</state>
        <zip>8091</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baden Cantonal Hospital</name>
      <address>
        <city>Baden</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <contact>
      <last_name>Leonhard Schäffer, MD</last_name>
      <phone>+41 56 486 35 07</phone>
      <email>leonhard.Schaeffer@ksb.ch</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <contact>
      <last_name>Gwendolin Manegold-Brauer, MD</last_name>
      <phone>+41 61 265 90 46</phone>
      <email>Gwendolin.Manegold-Brauer@usb.ch</email>
    </contact>
    <contact_backup>
      <last_name>Sven Wellmann, Prof</last_name>
      <phone>+41 61 704 29 24</phone>
      <email>sven.wellmann@ukbb.ch</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Saint Gallen Cantonal Hospital</name>
      <address>
        <city>Saint Gallen</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <contact>
      <last_name>Tina Fischer, MD</last_name>
      <phone>+41 71 494 18 66</phone>
      <email>tina.fischer@kssg.ch</email>
    </contact>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>September 24, 2018</study_first_submitted>
  <study_first_submitted_qc>October 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 3, 2018</study_first_posted>
  <last_update_submitted>October 2, 2018</last_update_submitted>
  <last_update_submitted_qc>October 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>caesarean section</keyword>
  <keyword>Oxytocin challenge test</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Pulmonary Valve Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

